Medical device developer Access Vascular has raised $3.7 million to support its HydroPICC catheter designed to reduce thrombotic risk.
The HydroPICC is a peripherally inserted central catheter which the Bedford, Mass.-based company claims can significantly reduce the accumulation of platelets and the risk of thrombosis.
AngelMD Access Vascular syndicate co-lead Arun Jagannathan, MD, said the firm was impressed with the expertise and dedication of the team, as well as Access Vascular’s novel approach to addressing a critical unmet need in venous access.
“By leveraging its bulk hydrophilic biomaterial, Access Vascular’s devices have the potential to eliminate thrombosis and the cascade of complications that arise with the currently available devices,” Dr. Jagannathan said. VTN
READ MORE: Access Vascular
